Information:
Error:
ID
12251
Description
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072
Keywords
Versions (2)
- 10/1/15 10/1/15 -
- 10/28/15 10/28/15 -
Uploaded on
October 28, 2015
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
CLL Follow-Up Disease tranformation BO17072 NCT00090051
Follow-Up Disease tranformation of Chronic lymphocytic leukemia NCT0090051
Similar models
Follow-Up Disease tranformation of Chronic lymphocytic leukemia NCT0090051
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Progressive disease due to transformation to an more aggressive histology
Date of transformation
Item
Date of transformation
date
C0011008 (UMLS CUI [1])
CL Item
PLL (>55% prolymphocytes) (1)
C0023486 (UMLS CUI-1)
CL Item
Richter's Syndrome (see below) (2)
C0349631 (UMLS CUI-1)
CL Item
Diffuse large B cell lymphoma (1)
C0079744 (UMLS CUI-1)
CL Item
Hodgkin’s disease (2)
C0019829 (UMLS CUI-1)
CL Item
Clinical diagnosis only (3)
C0332140 (UMLS CUI-1)
CL Item
Other, specify (4)
C0205394 (UMLS CUI-1)
CL Item
negative (1)
C0205160 (UMLS CUI-1)
CL Item
positive (2)
C1446409 (UMLS CUI-1)
CL Item
not done (3)
C1272696 (UMLS CUI-1)